RNU6-225P

Across TCGA pan-cancer cohorts, RNU6-225P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNU6-225P data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RNU6-225P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-225P expression acts as an unfavorable survival marker.

BLCA, MESO, and LUSC are the cancer types where RNU6-225P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	III,IV	0.051	0.684	<.001	72	view →
MESO	OS	Tertile	All	0.130	0.557	.019	54	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	54	view →
HNSC	OS	Tertile	All	0.126	0.363	.005	54	view →
KIRP	OS	Tertile	II,III,IV	0.148	0.771	<.001	54	view →
GBM	DFS	Tertile	All	0.084	0.300	<.001	27	view →
TGCT	DFS	Tertile	All	0.174	0.801	.041	18	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNU6-225P–BLCA (OS)

Open the BLCA breakdown →